PACIFIC EDGE LIMITED — Capital/Financing Update 2019

Jan 28, 2019

28 January 2019 Company Announcement

==> picture [222 x 54] intentionally omitted <==

PACIFIC EDGE SUCCESSFULLY COMPLETES CAPITAL RAISING

Pacific Edge Limited (NZX: PEB) advises that its Share Purchase Plan (SPP) has been successfully concluded and the offer has now closed. The issue price has been confirmed at $0.3427 per share.

The SPP was the second stage of Pacific Edge’s capital raising and followed a successful $7 million placement to selected institutions and other eligible persons which was completed on 30 November 2018.

Chair of Pacific Edge, Chris Gallaher, said: “The capital raising has seen a number of new local and international investors join Pacific Edge’s register and reflects the growing interest in our company from institutional investors and fund managers. We thank shareholders for their ongoing support with the successful share placement and the Share Purchase Plan closing at the top end of the indicative range.”

Pacific Edge is seeking to position Cxbladder as the preferred bladder cancer diagnostics tests for physicians, patients and healthcare providers, particularly in the USA, which is the world’s largest healthcare market. The company is also focused on its home market of New Zealand, as well as South East Asia and Australia. The funds raised provide extra capital resources to assist the company to progress its commercial objectives and become cash flow positive as soon as possible.

The SPP closed on 25 January 2019 and shares will be allotted on 31 January 2019.

ENDS

For more information contact:

David Darling Chief Executive Officer Pacific Edge Ltd P: +64 (3) 479 5800

OVERVIEW www.pacificedge.co.nz www.pacificedgedx.com

Pacific Edge Limited (NZX: PEB) is a New Zealand publicly listed, cancer diagnostic company specialising in the discovery and commercialisation of diagnostic and prognostic tests for better detection and management of cancer. Its Cxbladder suite of non-invasive, simple to use and accurate diagnostic tests provide actionable results, and better detection and management of urothelial cancer. The company is developing and commercialising its range of Cxbladder bladder cancer tests globally through its wholly owned central laboratories in New Zealand and the USA. The company’s products have been tested and validated in international multi-centre clinical studies.

ABOUT Cxbladder Triage www.cxbladder.com

Cxbladder Triage combines the power of the genomic biomarkers with additional phenotypic and clinical risk factors to accurately identify patients with haematuria who have a low probability of bladder cancer and may not require a more extensive urological evaluation. Cxbladder Triage is a tool for use by clinicians and physicians in primary evaluation of patients with haematuria and is intended to reduce the need for an expensive and invasive work-up in patients who have a low probability of having urothelial carcinoma.

ABOUT Cxbladder Detect www.cxbladder.com

Cxbladder Detect enables the non-invasive detection of bladder and other urinary tract cancers from a small volume of a patients’ urine. Cxbladder Detect provides clinicians with a quick, cost effective and accurate measure of the presence of the cancer as an effective adjunct to cystoscopy.

28 January 2019 Company Announcement

==> picture [222 x 54] intentionally omitted <==

ABOUT Cxbladder Monitor www.cxbladder.com

Cxbladder Monitor allows urologists to monitor bladder cancer patients for recurrence of the disease. Bladder cancer has a recurrence rate of 50-80% and requires life-long surveillance. Cxbladder Monitor accurately identifies patients with a prior history of urothelial cancer (UC) whose Cxbladder Monitor score shows that they have a low probability of recurrent urothelial carcinoma. Cxbladder Monitor is designed to be used as the preferred adjunct test to cystoscopy in the management of patients for ongoing evaluation of recurrent bladder cancer.

ABOUT Cxbladder Resolve www.cxbladder.com

Cxbladder Resolve identifies those patients who are likely to have aggressive or more advanced bladder cancer. Cxbladder Resolve, when used as part of the primary evaluation of haematuria and/or in conjunction with other Cxbladder tests (Triage, Detect), is designed to assist clinicians by accurately identifying patients with a high probability of having high grade or late stage bladder cancer, for whom alternative or expedited treatment options may be warranted, or who can be prioritised for further investigation in high throughput settings.

Refer to www.cxbladder.com for more information.